Repros Therapeutics Inc. (NASDAQ: RPRX) stock has broken to new high for the year with its receipt of Institutional Review Board approval to begin the phase IIb study of Androxal in men with secondary hypogonadism. The company submitted the protocol for FDA comment and planned to begin enrolling subjects in January.
The study is expected to enroll up to 120 men with morning testosterone levels < 250 ng/dl. The primary efficacy endpoint of the study is change in morning testosterone levels comparing the baseline visit to the levels achieved after three months to those achieved for placebo. The changes in pituitary hormones that control testicular function will be assessed as secondary efficacy measures.
The company also announced the public offering of 690,000 units, (including the exercise of the underwriter�s overallotment option), consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15. Each unit consists of four shares of common stock, Series A Warrants exercisable for three shares of common stock at an exercise price of $0.01 per share and Series B Warrants exercisable for 2.45 shares of common stock at an exercise price of $2.49 per share. The gross proceeds after the underwriting discount and before offering expenses are expected to be approximately $11 million. After the closing of this offering, the Series A Warrants and Series B Warrants will be listed on the Nasdaq Capital Market under the symbols �RPRXW� and �RPRXZ,� respectively. The offering was expected to be closed on or about February 8, 2011.
Repros Therapeutics stock is currently trading at $6.16, up 6.39% from its previous close. Repros Therapeutics shares touched the high of $6.85 and lowest price in today�s session is $5.55.
The company stock traded in the range of $1.11 and $6.85 during the past 52 weeks. The company�s market cap is $54.92 million. The company stock�s beta is 0.45.
- Want buy and sell signals? Premium newsletter, 15% off annual subscription – sign up today!
- Need fast service and cheap rates from a broker? Click here to see my favorite place to trade RPRX
- Want more? Check out the message board buzz for RPRX
- See which newsletters are recommending this stock pick
- Get breakingnews alerts on this stock:� http://thestockmarketwatch.com/
No comments:
Post a Comment